Czömpöly T et al. A possible new bridge between innate and adaptive immunity: Are the anti-mitochondrial citrate synthase autoantibodies components of the natural antibody network?. (2006) MOLECULAR IMMUNOLOGY 0161-5890 43 1761-1768,
1019443
Burbano Catalina et al. MICROPARTICLES THAT FORM IMMUNE COMPLEXES AS MODULATORY STRUCTURES IN AUTOIMMUNE RESPONSES. (2014) MEDIATORS OF INFLAMMATION 0962-9351 1466-1861 2014
Cauwe B et al. Deficiency of gelatinase B/MMP-9 aggravates lpr-induced lymphoproliferation and lupus-like systemic autoimmune disease. (2011) JOURNAL OF AUTOIMMUNITY 0896-8411 1095-9157 36 3-4 239-252
Fierabracci A. Unravelling autoimmune pathogenesis by screening random peptide libraries with human sera. (2009) IMMUNOLOGY LETTERS 0165-2478 124 1 35-43
Merrill JT. Chapter 14 Antiphospholipid Antibodies and Atherosclerosis. (2009) Megjelent: Antiphospholipid Syndrome in Systemic Autoimmune Diseases pp. 169-183
Berg PA. Autoimmunity in primary biliary cirrhosis: An alternative view at initiation and function of anti-mitochondrial autoantibodies. (2009) JOURNAL OF HEPATOLOGY 0168-8278 1600-0641 50 4 827-828
Asherson RA et al. Antiphospholipid antibodies and the antiphospholipid syndrome: Clinical significance and treatment. (2008) SEMINARS IN THROMBOSIS AND HEMOSTASIS 0094-6176 1098-9064 34 3 256-266
Herrmann S.H.. Antibody profiling for protein drug development and clinical development. (2007) Megjelent: Functional Protein Microarrays in Drug Discovery pp. 275-300
Czompoly T et al. Detailed analyses of antibodies recognizing mitochondrial antigens suggest similar or identical mechanism for production of natural antibodies and natural autoantibodies. (2008) AUTOIMMUNITY REVIEWS 1568-9972 7 6 463-467,
1612631
Reyneveld G. IJsbrand et al. Current Understanding of Natural Antibodies and Exploring the Possibilities of Modulation Using Veterinary Models. A Review. (2020) FRONTIERS IN IMMUNOLOGY 1664-3224 11
Becker Yann et al. Anti-mitochondrial autoantibodies in systemic lupus erythematosus and their association with disease manifestations. (2019) SCIENTIFIC REPORTS 2045-2322 9
Vujicic Ana Djordjevic et al. Natural autoantibodies in healthy neonatals recognizing a peptide derived from the second conserved region of HIV-1 gp120. (2014) VOJNOSANITETSKI PREGLED 0042-8450 71 4 352-361
Theoharides TC et al. The "missing link" in autoimmunity and autism: Extracellular mitochondrial components secreted from activated live mast cells. (2013) AUTOIMMUNITY REVIEWS 1568-9972 12 12 1136-1142
Stojanovich L. The Catastrophic Antiphospholipid Syndrome in Serbia: Diagnostic and Management Problems. (2009) CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY 1080-0549 36 2-3 98-103
Lutz HU et al. Natural antibodies in health and disease: An overview of the first international workshop on natural antibodies in health and disease. (2008) AUTOIMMUNITY REVIEWS 1568-9972 7 6 405-409
Simon D et al. Soluble gp130, an antagonist of IL-6 transsignaling, is elevated in uveitis aqueous humor.. (2008) INVESTIGATIVE OPHTHALMOLOGY AND VISUAL SCIENCE 0146-0404 1552-5783 49 9 3988-3991,
2285880
Chen Hui et al. Increased levels of IL-6, sIL-6R, and sgp130 in the aqueous humor and serum of patients with diabetic retinopathy. (2016) MOLECULAR VISION 1090-0535 22 1005-1014
Xu Haili et al. Exploration of early-life candidate biomarkers for childhood asthma using antibody arrays. (2016) PEDIATRIC ALLERGY AND IMMUNOLOGY 0905-6157 1399-3038 27 7 696-701
Huang Q et al. Comparison of the capsule biocompatibility of three types of intraocular lenses in vitro. (2016) ZHONGHUA SHIYAN YANKE ZAZHI / CHINESE JOURNAL OF EXPERIMENTAL OPHTALMOLOGY 2095-0160 34 5 402-407
Mondejar Jose-Juan et al. Levels of thrombopoietin in aqueous humor of patients with noninfectious acute anterior uveitis. (2015) CLINICAL OPHTHALMOLOGY 1177-5467 1177-5483 9 1285-1290
Chan Clara C et al. Keratoconus and crosslinking: pharmacokinetic considerations. (2013) EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY 1742-5255 1744-7607 9 12 1613-1624
Lewis AC. Interleukin-6 in the pathogenesis of posterior capsule opacification and the potential role for interleukin-6 inhibition in the future of cataract surgery. (2013) MEDICAL HYPOTHESES 0306-9877 1532-2777 80 4 466-474
Ebihara N et al. Role of the IL-6 Classic- and Trans-Signaling Pathways in Corneal Sterile Inflammation and Wound Healing. (2011) INVESTIGATIVE OPHTHALMOLOGY AND VISUAL SCIENCE 0146-0404 1552-5783 52 12 8549-8557
Sugaya S et al. Regulation of soluble interleukin-6 (IL-6) receptor release from corneal epithelial cells and its role in the ocular surface. (2011) JAPANESE JOURNAL OF OPHTHALMOLOGY 0021-5155 55 3 277-282
Wendling D et al. Onset of Inflammatory Eye Disease Under Tocilizumab Treatment for Rheumatologic Conditions: A Paradoxical Effect?. (2011) JOURNAL OF RHEUMATOLOGY 0315-162X 1499-2752 38 10 2284-2285
Li Shizhe et al. Network pharmacology strategy for predicting the correlation of Systemic Scleroderma with Vitamin D deficiency. (2020) INTERNATIONAL IMMUNOPHARMACOLOGY 1567-5769 1878-1705 86
Priora Marta et al. Serological and clinical profile of systemic sclerosis: analysis in a cohort of patients from a single center in Northern Italy. (2018) GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA 0392-0488 1827-1820 153 1 33-38
Zian Zeineb et al. Immunological and Clinical Characteristics of Systemic Lupus Erythematosus: A Series from Morocco. (2018) BIOMED RESEARCH INTERNATIONAL 2314-6133 2314-6141
Maria Alexandre T et al. Adipose-Derived Mesenchymal Stem Cells in Autoimmune Disorders: State of the Art and Perspectives for Systemic Sclerosis. (2017) CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY 1080-0549 52 2 234-259
Kranenburg Pim et al. Survival and organ involvement in patients with limited cutaneous systemic sclerosis and anti-topoisomerase-I antibodies: determined by skin subtype or auto-antibody subtype? A long-term follow-up study. (2016) RHEUMATOLOGY (UNITED KINGDOM) 1462-0324 1462-0332 55 11 2001-2008
Perosa Federico et al. Anti-centromere protein A antibodies in systemic sclerosis: Significance and origin. (2016) AUTOIMMUNITY REVIEWS 1568-9972 15 1 102-109
van den Hombergh Wieneke M et al. An easy prediction rule for diffuse cutaneous systemic sclerosis using only the timing and type of first symptoms and auto-antibodies: derivation and validation. (2016) RHEUMATOLOGY (UNITED KINGDOM) 1462-0324 1462-0332 55 11 2023-2032
Cappella P. Use of flow cytometry for drug development of cell cycle inhibitor: The example of edotecarion, a topoisomerase I inhibitor. (2013) Megjelent: Drug Development: Principles, Methodology and Emerging Challenges pp. 63-87
Villalta D et al. Diagnostic accuracy and predictive value of extended autoantibody profile in systemic sclerosis. (2012) AUTOIMMUNITY REVIEWS 1568-9972 12 2 114-120
Arnson Y et al. Serum 25-OH vitamin D concentrations are linked with various clinical aspects in patients with systemic sclerosis: A retrospective cohort study and review of the literature. (2011) AUTOIMMUNITY REVIEWS 1568-9972 10 8 490-494
Lea P et al. Advantages of Multiplex Proteomics in Clinical Immunology The Case of Rheumatoid Arthritis: Novel IgXplex (TM) Planar Microarray Diagnosis. (2011) CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY 1080-0549 41 1 20-35
Jinnin M et al. Serum levels of soluble vascular endothelial growth factor receptor-2 in patients with systemic sclerosis. (2010) BRITISH JOURNAL OF DERMATOLOGY 0007-0963 1365-2133 162 4 751-758
Baraut J et al. Relationship between cytokine profiles and clinical outcomes in patients with systemic sclerosis. (2010) AUTOIMMUNITY REVIEWS 1568-9972 10 2 65-73
Cutolo M et al. Capillaroscopy as an outcome measure for clinical trials on the peripheral vasculopathy in ssc-is it useful?. (2010) INTERNATIONAL JOURNAL OF RHEUMATOLOGY 1687-9260 1687-9279 2010
Villalta D et al. Antibodies to fibrillarin, PM-Scl and RNA polymerase III detected by ELISA assays in patients with systemic sclerosis. (2010) CLINICA CHIMICA ACTA 0009-8981 1873-3492 411 9-10 710-713
Simon D et al. Naturally occurring and disease-associated auto-antibodies against topoisomerase I: a fine epitope mapping study in systemic sclerosis and systemic lupus erythematosus.. (2009) INTERNATIONAL IMMUNOLOGY 0953-8178 1460-2377 21 4 415-422,
1481154
Senecal Jean-Luc et al. Pathogenic roles of autoantibodies in systemic sclerosis: Current understandings in pathogenesis. (2019) JOURNAL OF SCLERODERMA AND RELATED DISORDERS 2397-1983
Glaeser L. et al. Molecular recognition patterns of anti-topoisomerase I-antibodies in patients with systemic sclerosis before and after autologous stem cell transplantation. (2018) CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 0392-856X 1593-098X 36 4 S28-S35
Fredi M et al. Anti-topoisomerase-I antibodies in systemic lupus erythematosus and potential association with the presence of anti-dsDNA antibodies. (2017) LUPUS 0961-2033 1477-0962 26 10 1121-1122
Mehta Heena et al. Topoisomerase I peptide-loaded dendritic cells induce autoantibody response as well as skin and lung fibrosis. (2016) AUTOIMMUNITY 0891-6934 49 8 503-513
Gao S et al. Effects of Lewis Y antigen on the gene expression of multiple drug resistance-associated proteins in human ovarian cancer RMG-I-H cells. (2010) MEDICAL ONCOLOGY 1357-0560 27 3 960-967
Minier T et al. Construct validity evaluation of the European Scleroderma Study Group activity index, and investigation of possible new disease activity markers in systemic sclerosis. (2010) RHEUMATOLOGY (UNITED KINGDOM) 1462-0324 1462-0332 49 6 1133-1145,
1494649
Doyen M. et al. Comparison of the disease activity score and the revised EUSTAR activity index in diffuse cutaneous systemic sclerosis patients. (2020) CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 0392-856X 1593-098X 38 3 S53-S58
Pauling John D. et al. Patient-reported outcome instruments in clinical trials of systemic sclerosis. (2019) JOURNAL OF SCLERODERMA AND RELATED DISORDERS 2397-1983
Ross Laura et al. The challenges and controversies of measuring disease activity in systemic sclerosis. (2018) JOURNAL OF SCLERODERMA AND RELATED DISORDERS 2397-1983 3 2 115-121
Ayhan Z et al. Association between Skin Thickness Measurements with Corneal Biomechanical Properties and Dry Eye Tests in Systemic Sclerosis. (2018) OCULAR IMMUNOLOGY AND INFLAMMATION 0927-3948
Bissell Lesley-Anne et al. Primary myocardial disease in scleroderma-a comprehensive review of the literature to inform the UK Systemic Sclerosis Study Group cardiac working group. (2017) RHEUMATOLOGY (UNITED KINGDOM) 1462-0324 1462-0332 56 6 882-895
Tay Tien et al. Measures of disease status in systemic sclerosis: A systematic review. (2017) SEMINARS IN ARTHRITIS AND RHEUMATISM 0049-0172 1532-866X 46 4 473-487
Tay Tien et al. Early accrual of organ damage in systemic sclerosis: rationale for development of a disease damage index. (2017) JOURNAL OF SCLERODERMA AND RELATED DISORDERS 2397-1983 2 2 127-134
Bissell Lesley-Anne et al. Consensus best practice pathway of the UK Systemic Sclerosis Study group: management of cardiac disease in systemic sclerosis. (2017) RHEUMATOLOGY (UNITED KINGDOM) 1462-0324 1462-0332 56 6 912-921
Rangarajan Vibhav et al. Cardiac complications of systemic sclerosis and management: recent progress. (2017) CURRENT OPINION IN RHEUMATOLOGY 1040-8711 29 6 574-584
Gigante Antonietta et al. Lung ultrasound in systemic sclerosis: correlation with high-resolution computed tomography, pulmonary function tests and clinical variables of disease. (2016) INTERNAL AND EMERGENCY MEDICINE 1828-0447 11 2 213-217
Melsens K et al. Disease activity indices in systemic sclerosis: a systematic literature review. (2016) CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 0392-856X 1593-098X 34 5 S186-S192
Suliman YA et al. Clinical trial design in systemic sclerosis. (2016) Megjelent: Scleroderma: From Pathogenesis to Comprehensive Management pp. 623-635
Morrisroe Kathleen B et al. Musculoskeletal Manifestations of Systemic Sclerosis. (2015) RHEUMATIC DISEASE CLINICS OF NORTH AMERICA 0889-857X 41 3 507-+
Andreoli L. et al. Disease activity assessment of rheumatic diseases during pregnancy: a comprehensive review of indices used in clinical studies. (2015) AUTOIMMUNITY REVIEWS 1568-9972 18 2 164-176
Folyóiratcikk/Sokszerzős vagy csoportos szerzőségű szakcikk (Folyóiratcikk)/Tudományos[30384749] [Egyeztetett]
Nihtyanova S I et al. Current management strategies for systemic sclerosis. (2014) CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 0392-856X 1593-098X 32 2 S156-S164
Becker C. Validierung der deutschen Fassung des „Scleroderma Health Assessment Questionnaire“ zur Erfassung der funktio nalen Gesundheit bei Patienten mit Systemischer Sklerose. (2013)
Muangchan C et al. The significance of interleukin-6 and C-reactive protein in systemic sclerosis: a systematic literature review. (2013) CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 0392-856X 1593-098X 31 2 S122-S134
Muangchan C et al. The 15% Rule in Scleroderma: The Frequency of Severe Organ Complications in Systemic Sclerosis. A Systematic Review. (2013) JOURNAL OF RHEUMATOLOGY 0315-162X 1499-2752 40 9 1545-1556
Decuman S et al. Work participation and work transition in patients with systemic sclerosis: a cross-sectional study. (2012) RHEUMATOLOGY (UNITED KINGDOM) 1462-0324 1462-0332 51 2 297-304
Muangchan Chayawee et al. Association of C-reactive protein with high disease activity in systemic sclerosis: Results from the Canadian Scleroderma Research Group. (2012) ARTHRITIS CARE & RESEARCH 2151-464X 2151-4658 64 9 1405-1414
Ibn Yacoub Y et al. Assessment of fatigue and its relationships with disease-related parameters in patients with Systemic sclerosis. (2012) CLINICAL RHEUMATOLOGY 0770-3198 1434-9949 31 4 655-660
Takács G et al. Insulin and leptin plasma levels after the microinjection of interleukin-1β into the nucleus accumbens of the rat. (2012) ACTA PHYSIOLOGICA HUNGARICA 0231-424X 1588-2683 2498-602X 99 4 472-478,
2103748
Csuka D et al. Serum concentration of immunoglobulin G-type antibodies against the whole Epstein–Barr nuclear antigen 1 and its aa35–58 or aa398–404 fragments in the sera of patients with systemic lupus erythematosus and multiple sclerosis. (2013) CLINICAL AND EXPERIMENTAL IMMUNOLOGY 0009-9104 1365-2249 171 3 255-262,
2175109
Guan Y. et al. The role of Epstein-Barr virus in multiple sclerosis: From molecular pathophysiology to in vivo imaging. (2019) NEURAL REGENERATION RESEARCH 1673-5374 1876-7958 14 3 373-386
Li Z.-X. et al. The risk of systemic lupus erythematosus associated with Epstein–Barr virus infection: a systematic review and meta-analysis. (2018) CLINICAL AND EXPERIMENTAL MEDICINE 1591-8890 1591-9528
Draborg Anette Holck et al. Impaired Cytokine Responses to Epstein-Barr Virus Antigens in Systemic Lupus Erythematosus Patients. (2016) JOURNAL OF IMMUNOLOGY RESEARCH 2314-8861 2314-7156 2016